Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.8% |
| 2 | Healthcare | 15.34% |
| 3 | Consumer Discretionary | 12.54% |
| 4 | Communication Services | 10.48% |
| 5 | Industrials | 8.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
Cinemark Holdings
CNK
$4.3B
| $2.87M | ﹤0.01% |
248,400
+32,600
| +15% | +$442K |
|
1502
ATI
ATI
$31B
| $2.87M | ﹤0.01% |
281,500
+37,000
| +15% | +$321K |
|
1503
Delek US
DK
$4.17B
| $2.86M | ﹤0.01% |
164,019
+19,700
| +14% | +$376K |
|
1504
Gentherm
THRM
$1.34B
| $2.85M | ﹤0.01% |
73,300
+10,000
| +16% | +$379K |
|
1505
Schneider National
SNDR
$6.42B
| $2.85M | ﹤0.01% |
115,500
+15,100
| +15% | +$332K |
|
1506
Range Resources
RRC
$9.47B
| $2.84M | ﹤0.01% |
505,100
+90,600
| +22% | +$503K |
|
1507
Twist Bioscience
TWST
$7.47B
| $2.84M | ﹤0.01% |
62,700
+8,100
| +15% | +$291K |
|
1508
Trupanion
TRUP
$1.35B
| $2.83M | ﹤0.01% |
66,310
+8,700
| +15% | +$281K |
|
|
VGR
1509
DELISTED
Vector Group Ltd.
VGR
| $2.82M | ﹤0.01% |
395,467
+72,192
| +22% | +$552K |
|
1510
Penske Automotive Group
PAG
$14.4B
| $2.81M | ﹤0.01% |
72,700
+2,000
| +3% | +$69.8K |
|
1511
CBIZ
CBZ
$2.96B
| $2.81M | ﹤0.01% |
117,300
+16,100
| +16% | +$365K |
|
|
ICPT
1512
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.81M | ﹤0.01% |
58,700
+7,900
| +16% | +$610K |
|
|
NAV
1513
DELISTED
Navistar International
NAV
| $2.81M | ﹤0.01% |
99,700
+13,200
| +15% | +$313K |
|
1514
Heron Therapeutics
HRTX
$63.2M
| $2.81M | ﹤0.01% |
191,000
+25,100
| +15% | +$412K |
|
1515
SITE Centers
SITC
$157M
| $2.8M | ﹤0.01% |
443,614
+58,192
| +15% | +$285K |
|
1516
Hilltop Holdings
HTH
$2.29B
| $2.8M | ﹤0.01% |
151,800
+11,200
| +8% | +$192K |
|
|
ADVM
1517
DELISTED
Adverum Biotechnologies
ADVM
| $2.8M | ﹤0.01% |
13,400
+1,900
| +17% | +$337K |
|
1518
Materion
MTRN
$5.98B
| $2.8M | ﹤0.01% |
45,500
+5,900
| +15% | +$298K |
|
|
RVNC
1519
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.79M | ﹤0.01% |
114,450
+24,400
| +27% | +$482K |
|
|
OPI
1520
DELISTED
Office Properties Income Trust
OPI
| $2.79M | ﹤0.01% |
107,533
+14,000
| +15% | +$364K |
|
1521
La-Z-Boy
LZB
$1.67B
| $2.78M | ﹤0.01% |
102,900
+12,900
| +14% | +$310K |
|
1522
Supernus Pharmaceuticals
SUPN
$2.74B
| $2.78M | ﹤0.01% |
117,100
+15,400
| +15% | +$340K |
|
|
PDCE
1523
DELISTED
PDC Energy, Inc.
PDCE
| $2.78M | ﹤0.01% |
223,514
+29,900
| +15% | +$357K |
|
1524
Champion Homes
SKY
$5.2B
| $2.77M | ﹤0.01% |
113,900
+15,000
| +15% | +$313K |
|
1525
Gray Television
GTN
$530M
| $2.77M | ﹤0.01% |
198,600
+17,000
| +9% | +$218K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.